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Diabetic Peripheral Neuropathic Pain (DPNP) is a common complication of diabetes, which 
affects a wide fraction of patients, and it’s likely to increase due to the prevalence of 
Diabetes. Diabetic neuropathy is a complication associated with patient age, illness course 
and hyperglycaemia severity. DPNP pharmacologic treatment includes antidepressants, 
anticonvulsants, and opioid drugs, among others. However, and given the different 
pharmacologic options, pain relief is currently unsatisfactory in most of the cases. 
The aim of this study was to systematically review randomized controlled trials of oral and 
topical pharmacotherapy for DPNP, including studies published in peer-reviewed journals 
in PUBMED and unpublished trials retrieved from ClinicalTrials.gov, reporting predefined 
efficacy and safety outcomes, published from 2010 on. Participants in these trials included 
people with diabetes mellitus and diabetic peripheral neuropathy who were given any 
treatment for diabetic peripheral neuropathy. Data from the trials were reviewed by two 
authors independently, and extracted using standardized data extraction sheets. From the 
29 selected trials, 11 were elected after exclusion criteria were applied; these trials included 
drugs with different pharmacotherapeutic profiles. Significant improvement of pain was 
only reported for two trials: one with a serotonin and norepinephrine reuptake inhibitor and 
other with a cholinergic agonist of the nicotinic receptors. Both these drugs present 
statistically significant differences in the intensity of the pain when compared to placebo. 
Further investigation in required to fully explain the mechanisms of the nerve injury in order 
to develop a target therapy for DPNP, with more efficient pain control. 
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